Please Wait a Moment
X

Articles

01May

CTS Implements HLA Class I and II Testing on the Gemini

01 May, 2019 | Return|

CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini on Monday, April 29th. As previously communicated, the Immucor assay and sample requirements are the same, and the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list are now available on our website.

 

 

 

 

Related

2020 Annual CTS Survey

The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...

Read More >

Phoenix Laboratory Transition to the VISION Analyzer

On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...

Read More >

Update on CTS Implementation of the Grifols Procleix Ultrio Elite Assay

In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...

Read More >
Long-time CTS Leader Josh Moon to Guide Operations as Chief Operating Officer

Long-time CTS Leader Josh Moon to Guide Operations as Chief Operating Officer

Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...

Read More >

CTS Tampa Implementation date change for Ultrio Elite

CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...

Read More >

FDA announces withdrawal of Guidance for ZIKV Testing

We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...

Read More >